title: Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies.
abstract: Antibodies have important roles in controlling cellular immunity through interaction with activating or inhibitory Fcγ receptors (FcγRs). FcγR engagement can facilitate receptor cross-linking on target cells, or induce retrograde FcγR signals to stimulate or suppress antibody-dependent, cell-mediated depletion of antigen-bearing target cells. Recent studies uncover unexpectedly important roles for FcγRs in the anticancer action of antibodies designed to trigger tumor cell apoptosis or enhance antitumor immunity. Here, we outline a conceptual framework for understanding these findings and discuss their mechanistic and translational implications.
authors: Department of Cancer Immunotherapy and Hematology, Genentech Inc., South San Francisco, CA 94080, USA.
authors: Jeong M
authors: JM
authors: Kim
authors: Avi
authors: A
authors: Ashkenazi
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D017452:Receptors, IgG / Q000378:metabolism*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000378:metabolism
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D017452:Receptors, IgG
references: Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8
references: 18635688
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: J Exp Med. 2005 Oct 3;202(7):885-91
references: 16186187
references: Immunity. 1997 Dec;7(6):885-95
references: 9430233
references: Immunity. 1994 Aug;1(5):405-13
references: 7882171
references: J Exp Med. 2013 Aug 26;210(9):1685-93
references: 23897982
references: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15059-64
references: 14608036
references: Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10
references: 16537476
references: Nat Immunol. 2002 Jan;3(1):33-41
references: 11740498
references: Cancer Immunol Immunother. 2010 Sep;59(9):1367-77
references: 20480365
references: Science. 2011 Aug 19;333(6045):1030-4
references: 21852502
references: Expert Opin Biol Ther. 2006 Nov;6(11):1161-73
references: 17049014
references: Science. 1992 Jun 26;256(5065):1808-12
references: 1535455
references: Annu Rev Immunol. 2012;30:531-64
references: 22224781
references: Nat Rev Immunol. 2006 May;6(5):343-57
references: 16622479
references: J Immunol. 2004 Oct 15;173(8):5008-20
references: 15470044
references: Immunity. 1995 Nov;3(5):541-7
references: 7584144
references: Nat Rev Immunol. 2008 Jan;8(1):34-47
references: 18064051
references: Trends Immunol. 2001 Sep;22(9):510-6
references: 11525942
references: Science. 1995 Nov 10;270(5238):985-8
references: 7481803
references: Science. 2008 Oct 10;322(5899):271-5
references: 18845758
references: J Exp Med. 1995 Aug 1;182(2):459-65
references: 7543139
references: Science. 2005 Dec 2;310(5753):1510-2
references: 16322460
references: Biochem Soc Trans. 2002 Aug;30(4):487-90
references: 12196120
references: Nat Immunol. 2002 Feb;3(2):135-42
references: 11812990
references: J Exp Med. 2013 Aug 26;210(9):1695-710
references: 23897981
references: Int J Cancer. 2010 Aug 15;127(4):759-67
references: 20518016
references: Immunity. 2006 Jan;24(1):19-28
references: 16413920
references: Cancer Cell. 2011 Jan 18;19(1):101-13
references: 21251615
references: Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6181-6
references: 22474370
references: Nat Rev Drug Discov. 2009 Mar;8(3):226-34
references: 19247305
references: Eur J Immunol. 2004 Mar;34(3):613-622
references: 14991590
references: J Exp Med. 2004 Sep 20;200(6):771-82
references: 15381730
references: Immunity. 2002 Feb;16(2):311-23
references: 11869690